Pharmacotherapeutic considerations for psychiatric disorders: Depression

Formulary

Volumn 32, Issue 1, 1997, Pages

  Risby, Emile ^a   Donnigan, Deane ^b   Nemeroff, Charles B ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; AMOXAPINE; BEFLOXATONE; CLOMIPRAMINE; DESIPRAMINE; DOSULEPIN; DOXEPIN; DULOXETINE; FLESINOXAN; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MAPROTILINE; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NORTRIPTYLINE; PAROXETINE; PHENELZINE; PROTRIPTYLINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SUNEPITRON; TRANYLCYPROMINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENLAFAXINE;

AMNESIA; ATRIOVENTRICULAR BLOCK; CONSTIPATION; DEPRESSION; DROWSINESS; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG EFFICACY; DRUG MECHANISM; HEART BUNDLE BRANCH BLOCK; HUMAN; ORTHOSTATIC HYPOTENSION; REVIEW; SINUS TACHYCARDIA; TREATMENT OUTCOME; TREATMENT PLANNING; VISUAL IMPAIRMENT; XEROSTOMIA;

EID: 15144357657     PISSN: 00986909     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Regier DA, Boyd JH, Burke JD, et al. One-month prevalence of mental disorders in the United States: based on five Epidemiologic Catchment Area sites. Arch Gen Psychiatry 1988;5:977-86.
2. Regier DA, Narrow WE, Rae DS, et al. The de facto US mental and addictive disorders service system. Epidemiologic. Catchment Area prospective 1year prevalence rates of disorders and services. Arch Gen Psychiatry 1993; 50:85-94.
3. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Arch Gen Psychiatry 1994;51:8-19.
4. Kupfer DJ. Recurrent depression: prevention of a life long disorder. In: Keller MB, ed. Depression in the United States: Underrecognized and Undertreated? Minneapolis, Minn: McGrawHill Healthcare Publications 1994;29-35.
5. Broadhead WE, Blazer DG, George LK, Tse CK. Depression, disability days, and days lost from work in a prospective epidemiologic survey. JAMA 1990;264: 2524-8.
6. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders IV. 1994:282.
7. Livingston RL, Zucker DK, Isenberg K, Wetzel RD. Tricyclic antidepressants and delirium. J Clin Psychiatry 1983; 44:173-6.
8. Classman AH, Roose SP, Bigger JT Jr. The safety of tricyclic antidepressants in cardiac patients. Risk-benefit reconsidered. JAMA 1993;269:2673-5.
9. Halper J, Mann JJ. Cardiovascular effects of antidepressant medications. Br J Psychiatry 1988;1539(Suppl 3):87-98.
10. Depression Guideline Panel. Depression in Primary Care: Vol 2. Treatment of Major Depression. Clinical Practice Guideline, Number 5, Rockville MD: US Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research. AHCPR Publication No. 93-0551; April 1993.
11. McDaniel KD. Clinical pharmacology of monoamine oxidase inhibitors. Clin Neuropharmacol 1986;9:207-34.
12. Risby ED, Risch SC, Stoudemire A. Mood Disorders. In: Stoudemire A, ed. Clinical Psychiatry for Medical Students. 2nd ed. Philadelphia: JP Lippincott Co; 1994;l69-232.
13. White K, Simpson G. Combined MAOI-tricyclic antidepressant treatment: A re- evaluation. J Clin Psychopharmacol 1981;5:264-82.
14. Feighner JP, Boyer WF, Tyler DL, Nebrosky RJ. Adverse consequences of fluoxetine-MAOI combination therapy. J Clin Psychiatry 1990;51:222-5.
15. Sterinbach H. The serotonin syndrome. Am J Psychiatry 1991;148;705-13.
16. Uebowitz MR, Quitkin FM, Stewart JW, et al. Antidepressant specificity in atypical depression. Arch Gen Psychiatry 1988;45:129-37.
17. McGrath P, Stewart J, Harrison W et al. Predictive value of symptoms of atypical depression for differential drug outcome. J Clin Psychopharmacol 1992;12: 197-202.
18. Preskorn SH, Burke M. Somatic Therapy for Major Depressive Disorder: Selection of an Antidepressant. J Clin Psychiatry 1992;53(Suppl 9):5-18
19. Coryell W. Anxiety secondary to depression. Psychiatr Clin North Am 1990;13:685-98
20. Davidson J, Pelton S. Forms of atypical depression and their response to antidepressant drugs. Psychiatry Res 1986; 17:87-95.
21. Richelson E. Antidepressants and brain neurochemistry. Mayo Clin Proc 1990; 65:1227-36.
22. Leonard BE. Pharmacological differences of serotonin reuptake inhibitors and possible clinical relevance. Drugs 1992;43(Suppl 2):3-10.
23. Rickeis K, Schweizer E. Clinical overview of serotonin reuptake inhibitors. J Clin Psychiatry 1990;51(Suppl 12 B):9-12.
24. Crewe HK, Lennard MS, Tucker GT, et al. The effect of selective serotonin reuptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 1992;3-4:262-5.
25. Nemeroff CB, DeVane CL, Pollack BG. Newer Antidepressants and the cy- tochrome P450 system. Am J Psychiatry 1996;153:311-20.
26. Gardner EA. Johnston JA. Bupropion an antidepressant without sexual pathophysiological action. J Clin Psychopharmacol 1985;5:24-9.
27. Roose SP, Dalack GW, Classman AH, et al. Cardiovascular effects of bupropion in depressed patients with heart disease. Am J Psychiatry 1991;148:512-16.
28. Lineberry CG, Johnston JA, Raymond RN, et al. A fixed-dose efficacy study of bupropion and placebo in depressed outpatients. J Clin Psychiatry 1990;51: 194-9.
29. Weisler RH, Johnston JA, Lineberry CG, et al. Comparison of bupropion and trazodone for the treatment of major depression. J Clin Psychopharmacol 1994;14:170-9.
30. Feighner JP, Garder EA, Johnston JA, et al. Double-blind comparison of bupropion and fluoxetine in depressed outpatients. J Clin Psychiatry 1991;52:329- 35.
31. Alexopoulos GS. Treatment of depression. In Salzman C, ed. Clinical Geriatric Psychopharmacology. 2nd ed. Baltimore: Williams & Wilkins; 1992;148.
32. Rudorfer MV, Potter WZ. Antidepressants. A comparative review of the clinical pharmacology and therapeutic use of the 'newer' versus the 'older' drugs. Drugs 1989;37:713-8.
33. Warner MD, Peabody CA, Whiteford HA, Hollister LE. Trazadone and priapism. J Clin Psychiatry 1987;48:244-5.
34. Owens MJ, Ieni JR, Knight DL, et al. The serotonergic antidepressant nefazadone inhibits the serotonin transporter: In vivo and ex vivo studies Life Sciences 1995 57:373-80.
35. Muth EA, Haskins JT, Moyer JA, et al. Antidepressant biochemical profile of the novel bicyclic compound W445,030: An ethyl cyclohexamol derivative. Biochem Pharmacol 1986;35:4493- 7.
36. Schweizer E, Weise C, Clary C et al. Placebo-controlled trial of venlafaxine for the treatment of major depression. J Clin Psychopharmacol 1991;11:233-6.
37. Chow MSS. Focus on mirtazapine: A new antidepressant with noradrenergic and specific serotonergic activity. Formulary 1996;31:455-69.
38. de Boer T, Ruigt GSF. The selective alpha2-adrenoreceptor antagonist mirtazapine (Org 3770) enhances noradrenergic and 5-HT1A-mediated serotonergic neurotransmission. CNS Drugs 1995;49(Suppl 1):29-38.
39. Boston Consulting Group. The changing environment for U.S. pharmaceuticals: The role of pharmaceutical companies in a systems approach to health care. The Boston Consulting Group, Inc; 1993.
40. Sclar DA, Robison LM, Skater TL, et al. Antidepressant pharmacotherapy: Economic outcomes in a health maintenance organization. Clin Ther 1994; 16:715-31.
41. McFarlancl BH. Cost-effectiveness considerations for managed care systems: Treating depression in primary care. Am J Med 1994;97(Suppl (6A):S47-S58.
42. Jonsson B, Bebbington PE: What price depression? The cost of depression and the cost-effectiveness of pharmacological treatment. Br J Psychiatry 1994;164: 665-73.
43. Verbosky LA, Franco KN, Zrull JP. The relationship between depression and length of stay in the general hospital patients. J Clin Psychiatry 1993;54:177- 81.
44. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: Results from the national comorbidity survey. Arch Gen Psychiatry 1994;51:8-19.
45. Greenberg PE, Stiglin LE, Frankelstein SN, et al. The economic burden of depression in 1990. T Clin Psych 1993;54: 405-18.
46. Souetre, Lozet H, Martin P, et al. Work loss and depression: Impact of fluoxetine. Therapie 1993;48:81-8.
47. Le Pen C, Levy E, Ravily V, et al. The cost of treatment dropout in depression: A cost-benefit analysis of fluoxetine vs tricyclics. J Affect Discor 1994; 31:1-18.
48. Saklad SR. Pharmacoeconomic issues in the treatment of depression. Pharmacotherapy 1995;15:76S-83S.
49. The NDA Pipeline - 1995. Chevy Chase, MD: F-D-C Reports, Inc; 1996.
50. What's in the pipeline: A supplement to Med Ad News. West Trenton, NJ: Engel Publishing Partners; 1996.
51. New medicines in development for mental illnesses: 1996 survey. Washington, DC: Pharmaceutical Research and Manufacturers of America; 1996.